InspireMD, Inc. (NSPR)
NASDAQ: NSPR · Real-Time Price · USD
3.000
+0.020 (0.67%)
Dec 20, 2024, 4:00 PM EST - Market closed
InspireMD Employees
As of December 31, 2023, InspireMD had 66 total employees, including 65 full-time and 1 part-time employees. The number of employees increased by 10 or 17.86% compared to the previous year.
Employees
66
Change (1Y)
10
Growth (1Y)
17.86%
Revenue / Employee
$103,348
Profits / Employee
-$427,818
Market Cap
78.25M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
I-Mab | 220 |
Generation Bio Co. | 174 |
Rani Therapeutics Holdings | 140 |
Aerovate Therapeutics | 51 |
Ikena Oncology | 43 |
Ovid Therapeutics | 40 |
Genelux | 23 |
Unicycive Therapeutics | 14 |
NSPR News
- 12 days ago - InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR) - GlobeNewsWire
- 26 days ago - InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors - GlobeNewsWire
- 5 weeks ago - InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System - GlobeNewsWire
- 2 months ago - InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System - GlobeNewsWire
- 3 months ago - InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System - GlobeNewsWire
- 4 months ago - InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript - Seeking Alpha